Hormonal
High-intensity aerobic exercise stimulates mitochondrial protein synthesis (MitoPS) in late recovery (24-28h), whereas low-intensity exercise does not, although neither intensity stimulated MitoPS in early recovery (0.5-4.5h) in the fasted state.
If you are doing fasted cardio, high-intensity intervals may be more effective than low-intensity steady state for stimulating mitochondrial protein synthesis in the 24-28 hour window after exercise. Low-intensity cardio did not stimulate mitochondrial synthesis in this study, regardless of intensity, in the early recovery phase.
Over 24–28 h postexercise, MitoPS was significantly greater after the HIGH vs. LOW exercise trial (P < 0.05). Rates of MyoPS were increased equivalently over 0.5– 4.5 h postexercise recovery (P < 0.05) but remained elevated at 24 –28 h postexercise only following the HIGH trial.
Why this rating
Clear statistical difference in late recovery MitoPS between HIGH and LOW, but limited by small sample size and lack of early MitoPS stimulation.
Source
Influence of aerobic exercise intensity on myofibrillar and mitochondrial protein synthesis in young men during early and late postexercise recovery
Danielle M. Di Donato et al. · American Journal of Physiology-Endocrinology and Metabolism · 2014
DOI 10.1152/ajpendo.00487.2013
More from this paper
- High-intensity aerobic exercise (60% Wmax) sustains myofibrillar protein synthesis (MyoPS) into late recovery (24-28h), whereas low-intensity exercise (30% Wmax) does not, despite both stimulating early recovery MyoPS.Good
- High-intensity aerobic exercise stimulates mTOR phosphorylation (Ser2448) early in recovery (0.5h), which correlates with sustained myofibrillar protein synthesis, whereas low-intensity exercise does not.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →